Skip to main content
Control Bionics logo

Control Bionics

Milford, Ohio

  • Neurorehabilitation and assistive tech
  • Wearables
  • Series B

Control Bionics is a neurotechnology company developing non-invasive neural-signal technology for rehabilitation, performance, research, and assistive communication. Its platform combines surface EMG sensing, software, and medical-device validation to support measurable outcomes in clinical and real-world settings.

Latest round
Series B
Investor
1
Employees
11–50

reccy insights

Recent highlights

On Dec 3, 2025, Control Bionics acquired NeuroBounce. A separate company announcement reported the completion of an acquisition of U.S.-based Neuro Elite Athletics on Dec 31, 2025, extending the company’s reported acquisition activity. On Jan 30, 2026, the company announced a distribution deal, followed by a report that its shares extended gains for a second session. On Mar 26, 2026, it announced its first U.S. letter of intent connected to its iOS speech device program, describing a prospective commercial collaboration in that market. These developments point to activity in both commercial distribution and U.S. market development, alongside acquisitions. No awards or formal leadership appointments are identified in the available company information. The latest listed hiring signal says there were no current openings as of May 2026; that is a dated snapshot, not confirmation of current hiring conditions.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes Control Bionics distinct

  1. 01A shared neural-signal platform supports clinical, research, performance, and assistive communication applications.
  2. 02Combines surface EMG expertise with software and medical-device validation for complex clinical environments.
  3. 03Offers an integrated product ecosystem spanning signal capture, device control, and clinical use.
  4. 04Its technology is described as cleared by the FDA, TGA, and CE, with activity in Australia, the United States, Canada, and Japan.
  5. 05Focuses on expanding independence for people with complex physical needs.

Technology & products6

  • NeuroNode Trilogy

    A speech-generating device combining touch, eye control, and EMG/spatial control for flexible communication.

  • NeuroNode Duo

    A speech-generating device with EMG and spatial control options, flexible placement, and minimal-movement activation.

  • EyeGaze Duo

    A speech-generating device offering touch or eye-gaze access, including eye control of a computer mouse.

Recent updates3

  • Mar 26, 2026Partnership

    Control Bionics announced its first U.S. letter of intent related to its iOS speech device program, indicating a prospective commercial collaboration in the U.S. market.

    tradingview.com
  • Jan 30, 2026Partnership

    The company announced a new distribution deal for its products.

    tradingview.com
  • Oct 13, 2025Product launch

    Oskol 2: Eye Gaze Communication, Redefined

    controlbionics.com

In the Cortex

Funding

  • IPODec 2020
  • Series B
  • Series A
    Nightingale Partners
Latest valuation USD 37,077,988 (IPO valuation)1 investor

Similar companies

About Control Bionics

Products
NeuroNode Trilogy, NeuroNode Duo, EyeGaze Duo, Uno Touch, NeuroNode, Cosmos Connect
Leadership
Peter Ford, Founder and ChairmanJeremy Steele, Chief Executive Officer
Focus areas
Neurotechnology, medical devices, assistive technology, rehabilitation, augmentative and alternative communication, surface EMG, wearables, clinical technology
Headquarters
Milford, Ohio
Employees
11–50
Patents granted
9
Trademarks
30